Drugs / veliflapon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00353067 | May 2006 → ? | acute coronary syndrome | deCODE genetics | Suspended | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | veliflapon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00353067 ↗ |
| Known as | BAY X 1005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL88712 ↗ |
| Known as | BAY-X-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL88712 ↗ |
| Known as | DG-031 | “veliflapon (DG-031)” NCT00353067 ↗ |
| Action | Inhibit | “5-lipoxygenase activating protein inhibitor” CHEMBL88712 ↗ |
| Modality | Small molecule | — CHEMBL88712 ↗ |
| Target | ALOX5AP | “5-lipoxygenase activating protein inhibitor” CHEMBL88712 ↗ |